HPLC with UV or mass spectrometric detection for quantifying endogenous uracil and dihydrouracil in human plasma

Clinical Chemistry

Volumn 54, Issue 9, 2008, Pages 1463-1472

  Švobaite, Ruta ^a,b   Solassol, Isabelle ^c   Pinguet, Frederic ^c   Ivanauskas, Liudas ^b   Brès, Janine ^a   Bressolle, Françoise M M ^a,c  

^a UNIV MONTPELLIER   (France)

^b KAUNAS UNIVERSITY OF MEDICINE   (Lithuania)

^c CENTRE VAL D AURELLE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; DIHYDROURACIL; URACIL;

ARTICLE; BLOOD LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INTERMETHOD COMPARISON; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; METABOLIC DISORDER; SENSITIVITY AND SPECIFICITY; SOLID PHASE EXTRACTION; ULTRAVIOLET SPECTROSCOPY;

CALIBRATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HUMANS; HYDROXYLATION; MASS SPECTROMETRY; MOLECULAR STRUCTURE; NEOPLASMS; SOLVENTS; SPECTROPHOTOMETRY; URACIL;

EID: 51349144798     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1373/clinchem.2007.102251     Document Type: Article

References (38)

1. Longley DB, Harkin DP, Johnston PG. 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 2003;3:330-8.
2. Milano G, Roman P, Khater P, Frenay M, Renee N, Namer M. Dose versus pharmacokinetics for predicting tolerance to 5-day continuous infusion of 5-FU. Int J Cancer 1988;41:537-41.
3. Gamelin EC, Danquechin-Dorval EM, Dumesnil YF, Maillart PJ, Goudier MJ, Burtin PC, et al. Relationship between 5-fluorouracil (5-FU) dose intensity and therapeutic response in patients with advanced colorectal cancer receiving infusional therapy containing 5-FU. Cancer 1996;77:441-51.
4. Ychou M, Duffour J, Kramar A, Debrigode C, Gourgou S, Bressolle F, Pinguet F. Individual 5-FU dose adaptation in metastatic colorectal cancer: results of a phase II study using a bimonthly pharmacokinetically intensified LV5FU2 regimen. Cancer Chemother Pharmacol 2003;52:282-90.
5. Santini J, Milano G, Thyss A, Renee N, Viens P, Ayela P, et al. 5-FU therapeutic monitoring with dose adjustment leads to an improved therapeutic index in head and neck cancer. Br J Cancer 1989;59:287-90.
6. Etienne MC, Lagrange JL, Dassonville O, Fleming R, Thyss A, Renée R, et al. Population study of dihydropyrimidine dehydrogenase in cancer patients. J Clin Oncol 1994;12:2248-53.
7. Diasio RB, Harris BE. Clinical pharmacology of 5-fluorouracil. Clin Pharmacokinet 1989;16:215-37.
8. Milano G, Chamorey AL. Clinical pharmacokinetics of 5-fluorouracil with consideration of chronopharmacokinetics. Chronobiol Int 2002;19:177-89.
9. Lu Z, Zhang R, Diasio RB. Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: population characteristics, newly identified deficient patients, and clinical implication in 5-fluorouracil chemotherapy. Cancer Res 1993;53:5433-8.
10. Harris BE, Song R, Soong SJ, Diasio RB. Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion. Cancer Res 1990;50:197-201.
11. Milano G, Etienne MC. Potential importance of dihydropyrimidine dehydrogenase (DPD) in cancer chemotherapy. Pharmacogenetics 1994;4:301-6.
12. Gardiner SJ, Begg EJ, Robinson BA. The effect of dihydropyrimidine dehydrogenase deficiency on outcomes with fluorouracil. Adverse Drug React Toxicol Rev 2002;21:1-16.
13. Van Kuilenburg AB, Haasjes J, Richel DJ, Zoetekouw L, Van Lenthe H, De Abreu RA, et al. Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: identification of new mutations in the DPD gene. Clin Cancer Res 2000;6:4705-12.
14. Johnson MR, Diasio RB. Importance of dihydropyrimidine dehydrogenase (DPD) deficiency in patients exhibiting toxicity following treatment with 5-fluorouracil. Adv Enzyme Regul 2001;41:151-7.
15. Usuki H, Ishimura K, Yachida S, Hagiike M, Okano K, Izuishi K, et al. Dihydropyrimidine dehydrogenase (DPD) activity in gastric cancer tissue and effect of DPD inhibitory fluoropyrimidines. Gastric Cancer 2003;6(Suppl 1):66 -70.
16. Gamelin E, Boisdron-Celle M, Guérin-Meyer V, Delva R, Lortholary A, Genevieve F, et al. Correlation between uracil and dihydrouracil plasma ratio, fluorouracil (5-FU) pharmacokinetic parameters, and tolerance in patients with advanced colorectal cancer: a potential interest for predicting 5-FU toxicity and determining optimal 5-FU dosage. J Clin Oncol 1999;17:1105-10.
17. Tuchman M, Stoeckeler JS, Kiang DT, O'Dea RF, Ramnaraine ML, Mirkin BL. Familial pyrimidinemia and pyrimidinuria associated with severe fluorouracil toxicity. N Engl J Med 1985;313:245-9.
18. Fleming RA, Milano G, Thyss A, Etienne MC, Renée N, Schneider M, Demard F. Correlation between dihydropyrimidine dehydrogenase activity in peripheral mononuclear cells and systemic clearance of fluorouracil in cancer patients. Cancer Res 1992;52:2899-902.
19. Diasio RB, Beavers TL, Carpenter JT. Familial deficiency of dihydropyrimidine dehydrogenase: biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity. J Clin Invest 1988;81:47-51.
20. Meinsma R, Fernandez-Salguero P, Van Kuilenburg AB, Van Gennip AH, Gonzalez FJ. Human polymorphism in drug metabolism: mutation in the dihydropyrimidine dehydrogenase gene results in exon skipping and thymine uracilurea. DNA Cell Biol 1995;14:1-6.
21. Bi D, Anderson LW, Shapiro J, Shapiro A, Grem JL, Takimoto CH. Measurement of plasma uracil using gas chromatography-mass spectrometry in normal individuals and in patients receiving inhibitors of dihydropyrimidine dehydrogenase. J Chromatogr B 2000;738:249 -58.
22. Morimoto S, Mishima H, Tsujinaka T, Kawato N, Shono Y, Tsuji T, et al. Combined determination of urine uracil levels and plasma 5-FU clearance for a simple order-made treatment with anticancer agents of FU derivative [in Japanese]. Gan To Kagaku Ryoho 2003;30:89 -94.
23. Jiang H, Lu J, Ji J, Hu P. Important role of the dihydrouracil/uracil ratio in marked interpatient variations of fluoropyrimidine pharmacokinetics and pharmacodynamics. J Clin Pharmacol 2004;44:1260-72.
24. Jiang H, Lu J, Ji J. Circadian rhythm of dihydrouracil/ uracil ratios in biological fluids: a potential biomarker for dihydropyrimidine dehydrogenase levels. Br J Pharmacol 2004;141:616-23.
25. Boisdron-Celle M, Remaud G, Traore S, Poirier AL, Gamelin L, Morel A, Gamelin E. 5-Fluorouracil-related severe toxicity: a comparison of different methods for the pretherapeutic detection of dihydropyrimidine dehydrogenase deficiency. Cancer Lett 2007;249:271-82.
26. Déporte R, Amiand M, Moreau A, Charbonnel C, Campion L. High-performance liquid chromatographic assay with UV detection for measurement of dihydrouracil/uracil ratio in plasma. J Chromatogr B Analyt Technol Biomed Life Sci 2006;834:170-7.
27. Remaud G, Boisdron-Celle M, Hameline C, Morel A, Gamelin E. An accurate dihydrouracil/uracil determination using improved high performance liquid chromatography method for preventing fluoropyrimidines-related toxicity in clinical practice. J Chromatogr B Analyt Technol Biomed Life Sci 2005;823:98-107.
28. Ciccolini J, Mercier C, Blachon MF, Favre R, Durand A, Lacarelle B. A simple and rapid high-performance liquid chromatographic (HPLC) method for 5-fluorouracil (5-FU) assay in plasma and possible detection of patients with impaired dihydropyrimidine dehydrogenase (DPD) activity. J Clin Pharm Ther 2004;29:307-15.
29. Nakamura A, Kikuchi K, Ohishi T, Masuike T. Assay method for uracil, dihydrouracil, 5-fluorouracil and 5-fluoro-5, 6-dihydrouracil by high-performance liquid chromatography [in Japanese]. Gan To Kagaku Ryoho 2004;31:381-6.
30. Garg MB, Sevester JC, Sakoff JA, Ackland SP. Simple liquid chromatographic method for the determination of uracil and dihydrouracil plasma levels: a potential pretreatment predictor of 5-fluorouracil toxicity. J Chromatogr B Analyt Technol Biomed Life Sci 2002;774:223-30.
31. Gamelin E, Boisdron-Celle M, Turcant A, Larra F, Allain P, Robert J. Rapid and sensitive high-performance liquid chromatographic analysis of halogenopyrimidines in plasma. J Chromatogr B Biomed Sci Appl 1997;695:409-16.
32. Sparidans RW, Bosch TM, Jörger M, Schellens JH, Beijnen JH. Liquid chromatography-tandem mass spectrometric assay for the analysis of uracil, 5,6-dihydrouracil and beta-ureidopropionic acid in urine for the measurement of the activities of the pyrimidine catabolic enzymes. J Chromatogr B Analyt Technol Biomed Life Sci 2006;839:45-53.
33. van Kuilenburg AB, van Lenthe H, van Cruchten A, Kulik W. Quantification of 5,6-dihydrouracil by HPLC-electrospray tandem mass spectrometry. Clin Chem 2004;50:236-8.
34. Jiang H, Jiang J, Hu P, Hu Y. Measurement of endogenous uracil and dihydrouracil in plasma and urine of normal subjects by liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Life Sci 2002;769:169-76.
35. Bressolle F, Bromet-Petit M, Audran M. Validation of liquid chromatographic and gas chromatographic methods. Application to pharmacokinetics. J Chromatogr B Biomed Appl 1996;686:3-10.
36. US Food and Drug Administration. Guidance for industry. Bioanalytical method validation. http://www.fda.gov/cder/guidance/index.htm (Accessed May 2004).
37. Shah VP, Midha KK, Dighe S, McGilveray IJ, Skelly JP, Yacobi A, et al. Analytical methods validation: bioavailability, bioequivalence and pharmacokinetic studies [conference report]. Eur J Drug Metab Pharmacokinet 1991;16:249-55.
38. Matuszewski BK, Constanzer ML, Chavez-Eng CM. Matrix effect in quantitative LC/MS/MS analyses of biological fluids: a method for determination of finasteride in human plasma at picogram per milliliter concentrations. Anal Chem 1998;70:882-9.